PT - JOURNAL ARTICLE AU - Puzyrenko, Andrii AU - Jacobs, Elizabeth R. AU - Sun, Yunguang AU - Felix, Juan AU - Sheinin, Yuri AU - Ge, Linna AU - Lai, Shuping AU - Dai, Qiang AU - Nanchal, Rahul AU - North, Paula AU - Simpson, Pippa AU - Rui, Hallgeir AU - Benjamin, Ivor J. TI - Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78, a co-receptor for SARS-CoV-2, in COVID-19 autopsies AID - 10.1101/2021.06.17.21259098 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.17.21259098 4099 - http://medrxiv.org/content/early/2021/06/21/2021.06.17.21259098.short 4100 - http://medrxiv.org/content/early/2021/06/21/2021.06.17.21259098.full AB - Vaccinations are widely credited with reducing death rates from COVID-19 but the underlying host-viral mechanisms/interactions for morbidity and mortality of SARS-CoV-2 infection remain poorly understood. Acute respiratory distress syndrome (ARDS) describes the severe lung injury, which is pathologically associated with alveolar damage, inflammation, non-cardiogenic edema, and hyaline membrane formation. Because proteostatic pathways play central roles in cellular protection, immune modulation, protein degradation and tissue repair, we examined the pathological features for the unfolded protein response (UPR) using the surrogate biomarker glucose regulated protein 78 (GRP78) and co-receptor for SARS-CoV-2. At autopsy, immunostaining of COVID-19 lungs showed highly elevated expression of GRP78 in both pneumocytes and macrophages compared to non-COVID control lungs. GRP78 expression was detected in both SARS-CoV-2 infected and un-infected pneumocytes as determined by multiplexed immunostaining for nucleocapsid protein. In macrophages, immunohistochemical staining for GRP78 from deceased COVID-19 patients was increased but overlapped with GRP78 expression taken from surgical resections of non-COVID-19 controls. In contrast, the robust in situ GRP78 immunostaining of pneumocytes from COVID-19 autopsies exhibited no overlap and was independent of age, race/ethnicity and gender compared with non-COVID-19 controls. Our findings bring new insights for stress-response pathways involving the proteostatic network implicated for host resilience and suggest that targeting of GRP78 expression might afford an alternative therapeutic strategy to modulate host-viral interactions during SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project to IJB was provided by the Bruce and Janine Smith Family and the Deans Program Development Funds by the Department of Pathology Medical College of Wisconsin to HR and ERJ was supported by Merit Review BX003833. Childrens Research Institute and the Department of Pediatrics supported PS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board for Froedtert Hospital & Medical College of Wisconsin granted approval on August 19, 2020 for a waiver of HIPAA authorization requirements at 45 CFR 164 for the purpose of records review for this project. All decedent data was approved for access in accordance with 45 CFR 164.512. Project Title: Modeling Health Outcomes using HSP Biosignatures in COVID-19 High Risk Populations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsistent with National Institute of Health (NIH) plans for resource sharing, academic investigators will be granted access to deidentified information upon either publication and/or completion of our published and ongoing studies.